drugset / Trial / NCT07490275
Allogeneic CD19/BCMA-Targeted CAR-γδT Cell Therapy: Safety and Preliminary Pharmacodynamics in Relapsed/Refractory Autoimmune Diseases
NaSingle-groupOpen-labelTreatment
Summary
This study is a single-arm, intervention, dose-escalation clinical trial to evaluate the safety of allogeneic CD19/BCMA-targeted CAR-γδT cell in the treatment of relapsed/refractory autoimmune diseases
Timeline
- Start
- 2026-07-01
- Primary completion
- 2028-12-31
- Completion
- 2028-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Allogeneic CD19/BCMA-targeted CAR-γδT cell | Cell therapy | 5e+06 cells | — |
| Subject | Allogeneic CD19/BCMA-targeted CAR-γδT cell | Cell therapy | 1e+07 cells | — |
| Subject | Allogeneic CD19/BCMA-targeted CAR-γδT cell | Cell therapy | 1.5e+07 cells | — |
| Background | Cyclophosphamide | Other / unclassified | 300 mg/m2 | — |
| Background | Fludarabine | Small molecule | 30 mg/m2 | — |